No Data
Zhongxin Fluoride: 2024 Annual Results Forecast
Zhejiang Zhongxin Fluoride Materials (002915.SZ): Expected pre-loss of 0.18 billion yuan to -0.2 billion yuan for the 2024 fiscal year.
Gelonghui, January 17丨Zhejiang Zhongxin Fluoride Materials (002915.SZ) announced the annual performance forecast for 2024. The net income attributable to shareholders of the listed company is expected to be a loss of 0.18 billion yuan – 0.2 billion yuan, compared to a loss of 0.188 billion yuan in the same period last year; the net income after deducting non-recurring gains and losses is expected to be a loss of 0.167 billion yuan – 0.185 billion yuan, compared to a loss of 0.179 billion yuan in the same period last year; the basic EPS is expected to be a loss of 0.5506 yuan/share – 0.6118 yuan/share; revenue is expected to be 1.4 billion yuan – 1.42 billion yuan. During the reporting period, the company increased its efforts to expand the market for intermediate business and fluorine fine chemical business.
Retail Investors Invested in Zhejiang Zhongxin Fluoride Materials Co.,Ltd (SZSE:002915) Copped the Brunt of Last Week's CN¥1.0b Market Cap Decline
Investors in Zhejiang Zhongxin Fluoride MaterialsLtd (SZSE:002915) From Three Years Ago Are Still Down 44%, Even After 10% Gain This Past Week
10 consecutive trading limits! The big monster stock makes a comeback.
What exactly are you speculating about?
Zhejiang Zhongxin Fluoride Materials (002915.SZ): The company's pharmaceutical intermediates can be used in the field of CRO (Contract Research Outsourcing) pharmaceutical research and development.
Gelonghui October 18th: Zhejiang Zhongxin Fluoride Materials (002915.SZ) stated on the investor interaction platform that the company's pharmaceutical intermediates can be used in the field of CRO (Contract Research Outsourcing) pharmaceutical research and development. Pharmaceutical intermediates are important chemical raw materials in the drug synthesis process, playing a key role in the research and development of new drugs. Currently, the company has formed pharmaceutical intermediates represented by the 2,3,4,5-tetrafluorobenzene series, nanosar acid, and trifluoroacetic acid series. It has a provincial-level small and medium-sized enterprise technology center, a provincial-level enterprise research institute - Zhejiang Zhongxin Fluoride Chemicals and New Materials Research Institute, dedicated to pharmaceutical intermediates.
Zhejiang Zhongxin Fluoride Materials Co.,Ltd (SZSE:002915) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable